Survey on target treatment for lung cancer

Published: 2007-07-06 06:57:00
Updated: 2007-07-06 06:57:00
Four out of 10 doctors said a target agent for lung cancer would replace the conventional chemotherapeutic agents within the next five years, according to a recent survey conducted by AstraZeneca Korea (AZ Korea) which marked its seven-year launching of Iressa (gefinitib).

The survey of 162 sp...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.